Human Genome Epidemiology Literature Finder
Records 1 - 11 (of 11 Records) |
Query Trace: Nausea and BRAF[original query] |
---|
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 2012 Jul 380 (9839): 358-65. Hauschild Axel, Grob Jean-Jacques, Demidov Lev V, Jouary Thomas, Gutzmer Ralf, Millward Michael, Rutkowski Piotr, Blank Christian U, Miller Wilson H, Kaempgen Eckhart, Martín-Algarra Salvador, Karaszewska Boguslawa, Mauch Cornelia, Chiarion-Sileni Vanna, Martin Anne-Marie, Swann Suzanne, Haney Patricia, Mirakhur Beloo, Guckert Mary E, Goodman Vicki, Chapman Paul |
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. The Lancet. Oncology 2013 Jul 14 (8): 733-40. Robert Caroline, Dummer Reinhard, Gutzmer Ralf, Lorigan Paul, Kim Kevin B, Nyakas Marta, Arance Ana, Liszkay Gabriella, Schadendorf Dirk, Cantarini Mireille, Spencer Stuart, Middleton Mark |
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British journal of cancer 2017 Feb . Bendell Johanna C, Javle Milind, Bekaii-Saab Tanios S, Finn Richard S, Wainberg Zev A, Laheru Daniel A, Weekes Colin D, Tan Benjamin R, Khan Gazala N, Zalupski Mark M, Infante Jeffrey R, Jones Suzanne, Papadopoulos Kyriakos P, Tolcher Anthony W, Chavira Renae E, Christy-Bittel Janna L, Barrett Emma, Patnaik Ami |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer-A Case Series Study Target Therapy of BRAF-Mutated mCRC. Medicina (Kaunas, Lithuania) 2021 12 57 (12): . Yeh Jen-Hao, Tsai Hsiang-Lin, Chen Yen-Cheng, Li Ching-Chun, Huang Ching-Wen, Chang Tsung-Kun, Su Wei-Chih, Chen Po-Jung, Liu Yu-Peng, Wang Jaw-Yu |
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature medicine 2023 4 . Subbiah Vivek, Kreitman Robert J, Wainberg Zev A, Gazzah Anas, Lassen Ulrik, Stein Alexander, Wen Patrick Y, Dietrich Sascha, de Jonge Maja J A, Blay Jean-Yves, Italiano Antoine, Yonemori Kan, Cho Daniel C, de Vos Filip Y F L, Moreau Philippe, Fernandez Elena Elez, Schellens Jan H M, Zielinski Christoph C, Redhu Suman, Boran Aislyn, Passos Vanessa Q, Ilankumaran Palanichamy, Bang Yung-J |
Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation. The Journal of dermatology 2023 3 . Kaizuka Tomoaki, Kurihara Ryohei, Harumiya Miki, Kimura Takayuki, Ushida Nao |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: